DK3541784T5 - Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission - Google Patents

Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission Download PDF

Info

Publication number
DK3541784T5
DK3541784T5 DK17807779.8T DK17807779T DK3541784T5 DK 3541784 T5 DK3541784 T5 DK 3541784T5 DK 17807779 T DK17807779 T DK 17807779T DK 3541784 T5 DK3541784 T5 DK 3541784T5
Authority
DK
Denmark
Prior art keywords
modulators
derivatives useful
azetidine derivatives
novel azetidine
cortical
Prior art date
Application number
DK17807779.8T
Other languages
Danish (da)
English (en)
Other versions
DK3541784T3 (en
Inventor
Clas Sonesson
Fredrik Pettersson
Original Assignee
Integrative Res Laboratories Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integrative Res Laboratories Sweden Ab filed Critical Integrative Res Laboratories Sweden Ab
Publication of DK3541784T3 publication Critical patent/DK3541784T3/da
Application granted granted Critical
Publication of DK3541784T5 publication Critical patent/DK3541784T5/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK17807779.8T 2016-11-18 2017-11-17 Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission DK3541784T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16199545 2016-11-18
PCT/EP2017/079666 WO2018091687A1 (en) 2016-11-18 2017-11-17 Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission

Publications (2)

Publication Number Publication Date
DK3541784T3 DK3541784T3 (en) 2023-10-23
DK3541784T5 true DK3541784T5 (da) 2024-09-16

Family

ID=57348567

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17807779.8T DK3541784T5 (da) 2016-11-18 2017-11-17 Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission

Country Status (10)

Country Link
US (1) US10875829B1 (https=)
EP (1) EP3541784B1 (https=)
JP (1) JP6990702B2 (https=)
CN (1) CN109963834B (https=)
DK (1) DK3541784T5 (https=)
ES (1) ES2962865T3 (https=)
FI (1) FI3541784T3 (https=)
PL (1) PL3541784T3 (https=)
PT (1) PT3541784T (https=)
WO (1) WO2018091687A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112198237B (zh) * 2020-05-28 2021-08-06 扬子江药业集团广州海瑞药业有限公司 一种盐酸奈康唑杂质检测控制分析方法
KR20260033016A (ko) 2023-07-06 2026-03-10 인터그레이티브 리서치 래버러토리즈 스웨덴 에이비 병리적 무관심의 치료 및/또는 예방에 사용하기 위한 3-(2,3-디플루오로페녹시)아제티딘 또는 이의 약제학적으로 허용되는 염
CN121548563A (zh) 2023-07-06 2026-02-17 综合研究实验室瑞典股份公司 3-(2,3-二氟苯氧基)氮杂环丁烷的药学上可接受的盐及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004113297A2 (en) * 2003-06-24 2004-12-29 Neurosearch A/S Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2010022055A2 (en) 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
CA2744308C (en) 2008-11-24 2017-05-30 Nsab, Filial Af Neurosearch Sweden Ab, Sverige 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
MX2011005034A (es) 2008-11-24 2011-06-16 Nsab Af Neurosearch Sweden Ab Nuevos derivados de 3-fenil-azetidina utiles como moduladores de la neurotransmision catecolaminergica cortical.
EP2389374A1 (en) 2009-01-20 2011-11-30 Pfizer Inc. Substituted pyrazinone amides
TWI404721B (zh) * 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
WO2011103196A1 (en) 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
CA2836851C (en) 2011-06-07 2016-06-21 Christopher J. Helal Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
KR101273566B1 (ko) 2011-09-05 2013-06-11 한국과학기술연구원 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물
BR112014018199A8 (pt) * 2012-01-26 2021-03-02 H Lundbeck As inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
RU2017107521A (ru) 2014-08-27 2018-10-01 Ф. Хоффманн-Ля Рош Аг Замещенные производные азетидина в качестве лигандов рецепторов следовых аминов taar
EP3215500A1 (en) * 2014-11-05 2017-09-13 Dart NeuroScience (Cayman) Ltd. Substituted azetidinyl compounds as glyt1 inhibitors
PT3297987T (pt) * 2015-05-20 2019-06-19 Integrative Res Laboratories Sweden Ab Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica cortical
CN108026030B (zh) 2015-09-18 2020-10-09 正大天晴药业集团股份有限公司 一种氘代化合物的制备方法
TWI752098B (zh) * 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物

Also Published As

Publication number Publication date
WO2018091687A1 (en) 2018-05-24
JP2019535715A (ja) 2019-12-12
US10875829B1 (en) 2020-12-29
PL3541784T3 (pl) 2024-03-11
CN109963834A (zh) 2019-07-02
DK3541784T3 (en) 2023-10-23
FI3541784T3 (fi) 2023-10-02
EP3541784B1 (en) 2023-09-13
ES2962865T3 (es) 2024-03-21
EP3541784A1 (en) 2019-09-25
CN109963834B (zh) 2023-04-14
PT3541784T (pt) 2023-11-22
JP6990702B2 (ja) 2022-01-13

Similar Documents

Publication Publication Date Title
FR25C1013I1 (fr) Macrocycles de diaryle en tant que modulateurs de protéines kinases
LT3728238T (lt) Sulfonilkarbamido dariniai kaip nlrp3 uždegimo moduliatoriai
PL3507418T3 (pl) Sposoby biopochodnej derywatyzacji powierzchni celulozowych
EP3347372A4 (en) PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
DK3331876T3 (da) Modulators of ror-gamma
EP3509581A4 (en) FORMULATIONS OF (R
FR3021533B1 (fr) Composition cosmetique de type gel
HUE054009T2 (hu) Szubsztituált tetrahidrokinolinon vegyületek ROR gamma modulátorként
PT3645518T (pt) Síntese de omecamtiv mecarbil
EP3360010A4 (en) BI PHOTONS WITH VOTABLE SOURCE
EP3379139A4 (en) LAMPHOLDER
PT3457851T (pt) Derivados de sobetiroma
IL266505B (en) Heterocyclic modulators of lipid synthesis
EP3430816A4 (en) FRAME TRANSMISSION
HUE049606T2 (hu) Eljárás flavonoid inklúziós vegyületek elõállítására
PL3625224T3 (pl) Pochodne n-podstawionego indolu
BR112016026046A2 (pt) Uso de compostos de tienotriazolodiazepina
EP3688095A4 (en) POLYCARBONATE COMPOSITION
FR3023290B1 (fr) Derives de flavaglines
IL250613B (en) Substituted bicyclic compounds
EP3277701A4 (en) SYNTHESIS OF DESOSAMINES
PL3717523T3 (pl) Sposób modyfikacji ldpe
LT3347349T (lt) Fluorindolo dariniai kaip muskarininio m1 receptoriaus teigiami alosteriniai moduliatoriai
DK3541784T5 (da) Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
EP3171860C0 (en) SOLID ORAL FORMULATION OF FENRETINIDE